OAM
BBNX

Oxford Asset Management’s Beta Bionics BBNX Stock Holding History

Oxford Asset Management’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,500
Closed -$153K – 805
2025
Q1 		$153K Buy
+12,500
New +$233K 0.07% 393

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Oxford Asset Management's BBNX Position: Q2 2025 in Review

Oxford Asset Management sold out of Beta Bionics (BBNX) in Q2 2025, closing a stake of 12,500 shares — an estimated $153K sold.

Oxford Asset Management first reported a position in BBNX in Q1 2025 and held it in 1 quarter. The position peaked at $153K in Q1 2025. 116 funds tracked by Wall St. Rank hold BBNX as of Q2 2025.

  • Oxford Asset Management reported no remaining Beta Bionics position as of Q2 2025 after selling out during the quarter.
  • Oxford Asset Management sold 12,500 Beta Bionics shares in Q2 2025, an estimated $153K.
  • Oxford Asset Management first reported a position in Beta Bionics in Q1 2025 and held it in 1 quarter.
  • Oxford Asset Management's Beta Bionics position peaked at $153K in Q1 2025.
  • 116 funds tracked by Wall St. Rank held Beta Bionics as of Q2 2025.

Based on Oxford Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.